TB-500 and thymosin beta-4: peptide identity and research limits
TB-500 is a label that needs an exact material specification. A primary analytical paper identified Ac-LKKTETQ, an acetylated seven-residue fragment of thymosin beta-4, in the material it examined. That fragment and full-length thymosin beta-4 are not interchangeable, and a shared name does not verify a catalogue vial.
Full-length peptide, fragment and metabolite are different identities
Low and colleagues’ foundational 1981 sequence study characterised bovine thymosin beta-4 as a 43-residue peptide isolated from calf thymus. This is structural background about the full-length molecule, not an experiment on a current TB-500 product.
Esposito and colleagues’ 2012 analysis identified the N-terminally acetylated 17–23 fragment, Ac-LKKTETQ, in the TB-500 material they examined. The numbers 17–23 identify positions within thymosin beta-4; they describe a seven-residue fragment, not a 17- or 23-residue peptide. “Ac” denotes the acetyl modification.
What the 2012 analytical studies can establish
The researchers used chromatography and mass spectrometry, with a synthesised reference, to characterise the examined material. This supports an identity finding for that sample. It does not establish what every supplier means by TB-500, or which sequence is present in a separately supplied vial.
A separate 2012 study by Ho and colleagues detected the acetylated fragment and metabolites in horse samples. Detectability addresses an analytical question; it does not demonstrate clinical effectiveness.
The 2024 study separates the parent fragment from its metabolites
Rahaman and colleagues studied Ac-LKKTETQ in human serum, laboratory enzyme systems and rats, using a validated mass-spectrometric method. They also compared the parent fragment and metabolites in cultured fibroblasts.
In that fibroblast wound-closure screen, Ac-LKKTE showed a significant response against the control; the parent Ac-LKKTETQ did not. The distinction is specific to the tested conditions. It neither proves that the parent is inactive in every model nor establishes that a metabolite heals wounds in people. Human serum used outside the body is not a human treatment trial.
Match each finding to the molecule actually studied
The selected papers below explain identity and evidence attribution. This is not a complete literature review or a current regulatory assessment. A full-length thymosin beta-4 result should not be relabelled as evidence for the acetylated fragment, and a metabolite result should not silently become a parent-peptide claim.
| Primary study | Material and measurement | Boundary |
|---|---|---|
| Low et al., 1981 | Bovine full-length thymosin beta-4; amino-acid sequence. | Structural evidence for the isolated peptide, not catalogue-vial testing. |
| Esposito et al., 2012 | Acetylated 17–23 fragment; analytical identification. | A sample identity result, not clinical efficacy. |
| Ho et al., 2012 | Acetylated fragment and metabolites; equine-sample detection. | An analytical detection study, not an efficacy trial. |
| Rahaman et al., 2024 | Ac-LKKTETQ and metabolites; analytical and fibroblast experiments. | Keep the parent-fragment and metabolite findings separate. |
What a TB-500 specification and COA need to clarify
Ask for the exact peptide sequence, terminal modifications and the material that the assay identifies. Then read the reported mass or quantity, purity result and method on their own terms. A shorthand name or purity percentage alone cannot resolve a full-length-versus-fragment identity question.
Check the original sample description and batch identifier, and whether those identifiers are linked to the stock under review. If a report’s naming is ambiguous, obtain clarification from the supplier or issuing laboratory rather than inferring identity from a marketing label.
Keep FSD documentation separate from the literature
The FSD TB-500 listing links to its available laboratory records. Open the original report and read the reported analyte and stock-lot status. This guide does not independently determine whether current stock is full-length thymosin beta-4 or a fragment.
FSD materials are for laboratory research, not for human or veterinary administration. References here explain how to assess identity and study scope; they do not provide instructions for using a catalogue product in people.
Common questions
Is TB-500 always the same as full-length thymosin beta-4?
Do not assume so. The 2012 paper identified an acetylated fragment in its sample. Confirm the exact sequence and analytical documentation for the material being considered.
Does “17–23 fragment” mean the peptide has 17 amino acids?
No. Those are residue positions within thymosin beta-4. The fragment spans seven residues; it is distinct from the full-length 43-residue peptide described in the foundational sequence work.
Did the 2024 experiment show the same result for TB-500 and its metabolite?
No. In its fibroblast assay, the significant wound-closure finding belonged to Ac-LKKTE rather than parent Ac-LKKTETQ. This remains a laboratory result.
Does an analytical identification paper establish safety in people?
No. It addresses what was detected in the studied sample. It does not establish a human benefit–risk profile or verify another supplier’s material.
Sources & scope
These references explain analytical and research principles. They do not certify FSD BIO LABS or provide evidence about a particular FSD batch.
- Sequence characterisation of bovine thymosin beta-4 (1981) — Low et al. · Proceedings of the National Academy of Sciences
Foundational primary sequence study of a 43-residue peptide isolated from calf thymus. Structural context, not a study of catalogue TB-500 or clinical efficacy. - Identification of the acetylated thymosin beta-4 fragment in TB-500 (2012) — Esposito et al. · Drug Testing and Analysis
Primary analytical study identifying Ac-LKKTETQ in the examined TB-500 material using chromatography and mass spectrometry. It does not establish the identity of every product sharing that name. - TB-500 fragment detection in equine samples (2012) — Ho et al. · Journal of Chromatography A
Primary LC-MS detection study of N-acetylated LKKTETQ and metabolites in horse samples. Provides structural and analytical context; not evidence of human efficacy. - TB-500 fragment metabolism and fibroblast assay comparison (2024) — Rahaman et al. · Journal of Chromatography B
Primary analysis of Ac-LKKTETQ and metabolites in laboratory systems and rats, with a fibroblast activity screen. The parent and a metabolite had different assay results; neither is evidence of human treatment efficacy. - ICH Q2(R2): Validation of Analytical Procedures — FDA / ICH
Specificity, accuracy, precision, reportable range and the use of complementary analytical procedures; a method name alone does not establish fitness for a particular measurement. - ICH Q7: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients — FDA / ICH
Sections 11.4 and 17 describe COA contents, original report references and batch traceability. Used as a documentation benchmark; it does not establish FSD's GMP status.